Evidence map›Paper›PMID 27102770›Full record

ArticleThe American journal of pathology2016

TET2 Negatively Regulates Nestin Expression in Human Melanoma.

Camilla B F Gomes, Karina G Zechin, Shuyun Xu, Rafael F Stelini, Ines N Nishimoto, Qian Zhan, Ting Xu, Gungwei Qin, Nathaniel S Treister, George F Murphy and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in The American journal of pathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. PRAME Expression in Melanoma is Negatively Regulated by TET2-Mediated DNA Hydroxymethylation.Laboratory investigation; a journal of technical methods and pathology · 2025
    Article
  4. Expression ofCells · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Camilla B F GomesProgram in Oral Pathology, Department of Oral Diagnosis, School of Dentistry, University of Campinas, Piracicaba, Brazil; Program in Dermatopathology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Karina G ZechinProgram in Oral Pathology, Department of Oral Diagnosis, School of Dentistry, University of Campinas, Piracicaba, Brazil.
Shuyun XuProgram in Dermatopathology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Rafael F SteliniDepartment of Pathology, Medical Sciences School, University of Campinas, Piracicaba, Brazil.
Ines N NishimotoDepartment of Head and Surgery and Otorhinolaryngology, A.C. Camargo Cancer Center, São Paulo, Brazil.
Qian ZhanProgram in Dermatopathology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Ting XuProgram in Dermatopathology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Gungwei QinProgram in Dermatopathology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Nathaniel S TreisterDivision of Oral Medicine and Dentistry, Brigham and Women's Hospital, Harvard School of Dental Medicine, Boston, Massachusetts.
George F MurphyProgram in Dermatopathology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: gmurphy@rics.bwh.harvard.edu.
Christine G LianProgram in Dermatopathology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: cglian@bwh.harvard.edu.
Brigham and Women's Hospital · USUniversidade Estadual de Campinas (UNICAMP) · BRAC Camargo Hospital · BR

Funding

Immunology of human malignant melanoma initiating cellsR01CA158467 · NCI · BOSTON CHILDREN'S HOSPITAL · PI FRANK, MARKUS H., HODI, FRANK S · 2012 to 2016
$1.9M
NCI NIH HHS R01 CA158467
6 · The paper itself

Abstract

Although melanoma is an aggressive cancer, the understanding of the virulence-conferring pathways involved remains incomplete. We have demonstrated that loss of ten-eleven translocation methylcytosine dioxygenase (TET2)-mediated 5-hydroxymethylcytosine (5-hmC) is an epigenetic driver of melanoma growth and a biomarker of clinical virulence. We also have determined that the intermediate filament protein nestin correlates with tumorigenic and invasive melanoma growth. Here we examine the relationships between these two biomarkers. Immunohistochemistry staining of nestin and 5-hmC in 53 clinically annotated primary and metastatic patient melanomas revealed a significant negative correlation. Restoration of 5-hmC, as assessed in a human melanoma cell line by introducing full-length TET2 and TET2-mutated constructs, decreased nestin gene and protein expression in vitro. Genome-wide mapping using hydroxymethylated DNA immunoprecipitation sequencing disclosed significantly less 5-hmC binding in the 3' untranslated region of the nestin gene in melanoma compared to nevi, and 5-hmC binding in this region was significantly increased after TET2 overexpression in human melanoma cells in vitro. Our findings provide evidence suggesting that nestin regulation is negatively controlled epigenetically by TET2 via 5-hmC binding at the 3' untranslated region of the nestin gene, providing one potential pathway for understanding melanoma growth characteristics. Studies are now indicated to further define the interplay between 5-hmC, nestin expression, and melanoma virulence.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorCutaneous Malignant MelanomaDioxygenasesDNA-Binding ProteinsFemaleGene Expression Regulation, NeoplasticHumansImmunohistochemistryImmunoprecipitationMaleMelanomaMiddle AgedNestinBiomarkers, TumorDioxygenasesDNA-Binding ProteinsNES protein, humanNestinProto-Oncogene ProteinsTET2 protein, human

Identifiers

PMID27102770
PMCPMC4901139
OpenAlexW2337576177

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.